Atlanta, GA – Scibility Media – 10/28/2014.
This article discusses two stocks: Chiquita Brands International Inc(NYSE:CQB) and Baxano Surgical Inc(NASDAQ:BAXS)
Chiquita Brands International Inc(NYSE:CQB) announced on Oct. 27th that it had reached a definitive merger agreement with Cutrale-Safra group. The company’s outstanding shares will be acquired by Cutrale Group, a juice company, and Safra Group, a global financial services firm, for $14.50 per share in cash for a transaction valued at approximately $1.3 billion.
Following the announcement, the law firm of Levi & Korsinsky, LLP announced that it would be investigating the sale of Chiquita Brands International. The firm’s press release stipulated that one analyst had rated Chiquita’s stock at $16 per share, a figure which is $1.50 higher than the Cutrale-Safra group’s purchase price of $14.50.
Baxano Surgical Inc(NASDAQ:BAXS) is a North Carolina-based medical device company that develops and markets minimally invasive products for the treatment of degenerative conditions of the spine. The company markets the AxiaLIF family of products, the VEO lateral access and interbody fusion system, and the iO-Flex system.
Baxano Surgical has been on the decline recently, placing the stock at a rather affordable price of $0.16. The company has traded within a range of $0.10 to $1.75 over the past 52 weeks.
The company has received significant investor interest recently, recording a trading volume of over 5 million on Oct. 27th, 2014. Baxano Surgical has a market capitalization of over $6 million and 49.73 million tradeable shares.
EquiPress.com is a non-advertisement based network (currently in limited release) designed for investors to discover and communicate with publicly traded companies in real-time.
Sign-up for free now to experience the full benefits of EquiPress pre-launch.
Discover and communicate with companies you would otherwise never have seen based on your interests, company news, personalized news feeds, and one-on-one communications with no middle-men nor advertisements. Read our no advertisements pledge.
Can’t find your company on EquiPress? Send us an email to email@example.com and we will contact them for you.
Interested in a one month free trial? Get access to our private investor network, real-time news distribution, automatic disclaimers, corporate analytics, verified public profile, and industry-wide marketing of your corporate news.
Disclosure: EquiPress is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. EquiPress does not hold any equity or financial interest in any publicly traded company. EquiPress provides a uniform subscription based service to all publicly traded companies on a monthly basis at a rate of $495 to provide investor awareness. EquiPress receives only cash compensation from clients. Despite the relationship, EquiPress maintains a neutral stance (nonbiased) on any investment related opinions and exists solely for the purpose of allowing investors to communicate with the publicly traded companies in an effort to establish for themselves investment considerations. Investors should always conduct their own due diligence with any potential investment. Always seek help from a professional financial advisor. Please visit www.equipress.com for complete risks and disclosures.